IOVA IOVANCE BIOTHERAPEUTICS, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1425205 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY51.3%
TTM net income YoY44.5%
TTM EPS YoY58.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin53.2%
Operating margin-60.8%
Net margin-58.2%
FCF margin-57.0%
EBITDA margin-54.0%
Returns
ROE-29.1%
ROA-23.3%
ROIC (approx.)-28.0%
Asset turnover0.40x
Leverage & solvency
Liabilities / assets18.0%
Debt / equity0.00x
Current ratio5.20x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.86x
Accruals ratio-3.2%
Payout ratio—
Capex / revenue6.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $121.47M | $99.31M | $71.43M | $86.77M | $67.45M | $59.95M | $49.32M | $73.69M |
| Cost of revenue | $48.03M | $43.59M | $42.50M | $43.11M | $38.48M | $48.88M | $42.72M | $37.79M |
| Gross profit | $73.44M | $55.72M | $28.93M | $43.66M | $28.98M | $11.07M | $6.61M | $35.91M |
| R&D expense | $49.34M | $58.85M | $62.49M | $71.20M | $75.17M | $77.93M | $75.97M | $71.01M |
| SG&A expense | $38.58M | $39.27M | $38.95M | $36.40M | $34.55M | $37.57M | $43.80M | $42.32M |
| Operating income | -$23.97M | -$51.91M | -$81.04M | -$73.46M | -$94.90M | -$113.77M | -$121.22M | -$86.58M |
| Pretax income | -$21.66M | -$48.69M | -$79.71M | -$71.72M | -$93.66M | -$109.67M | -$118.00M | -$77.00M |
| Income tax | $614,000 | -$1.37M | -$665,000 | $184,000 | -$2.40M | $1.99M | -$1.84M | $1.56M |
| Net income | -$22.27M | -$47.31M | -$79.05M | -$71.90M | -$91.25M | -$111.66M | -$116.16M | -$78.56M |
| EBITDA | -$14.47M | -$42.41M | -$78.22M | -$69.74M | -$85.89M | -$104.42M | -$118.65M | -$83.30M |
| EPS (basic) | -0.05 | -0.11 | -0.19 | — | -0.25 | -0.33 | -0.36 | — |
| EPS (diluted) | -0.05 | -0.11 | -0.19 | — | -0.25 | -0.33 | -0.36 | — |
| Weighted avg. shares (diluted) | 455.92M | 450,189 | 418,511 | — | 364.04M | 334,511 | 322,868 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $57.93M | $110.77M | $196.51M | $163.08M | $158.13M | $132.47M | $171.67M | $122.05M |
| Short-term investments | $318.39M | $186.91M | $116.94M | $133.90M | $142.67M | $168.71M | $188.04M | $208.09M |
| Receivables | $106.99M | $102.12M | $81.76M | $82.45M | $66.76M | $59.94M | $70.94M | $69.34M |
| Inventory | $55.22M | $55.59M | $58.38M | $51.68M | $51.71M | $49.83M | $65.55M | $51.52M |
| Current assets | $549.63M | $464.26M | $466.50M | $442.69M | $429.09M | $422.50M | $512.65M | $457.02M |
| PP&E, net | $129.31M | $131.46M | $131.39M | $131.11M | $126.65M | $122.47M | $111.58M | $109.08M |
| Intangibles | $259.21M | $263.89M | $269.10M | $279.32M | $285.21M | $296.25M | $285.36M | $282.40M |
| Total assets | $991.21M | $915.53M | $925.66M | $913.17M | $904.95M | $907.44M | $966.74M | $910.43M |
| Current liabilities | $105.77M | $106.85M | $129.42M | $138.36M | $125.78M | $129.16M | $122.69M | $122.34M |
| Total liabilities | $178.55M | $179.49M | $203.91M | $214.59M | $202.66M | $208.95M | $198.88M | $200.02M |
| Shareholders' equity | $812.66M | $736.04M | $721.75M | $698.58M | $702.29M | $698.49M | $767.87M | $710.40M |
| Shares outstanding | 462.54M | 452.97M | 438.11M | 411.94M | 385.46M | 341.92M | 333.93M | 305.25M |
| Cash flow statement | ||||||||
| Operating cash flow | -$4.47M | -$60.84M | -$72.07M | -$52.56M | -$78.70M | -$67.45M | -$103.69M | -$73.30M |
| Capital expenditure | $4.74M | $5.44M | $6.61M | $9.32M | $10.84M | $7.46M | $6.21M | $4.17M |
| Free cash flow | -$9.21M | -$66.28M | -$78.68M | -$61.88M | -$89.55M | -$74.91M | -$109.91M | -$77.46M |
| Investing cash flow | -$134.65M | -$74.05M | $11.39M | $775,000 | $17.01M | $13.84M | $15.87M | $23.68M |
| Financing cash flow | $86.28M | $49.29M | $94.33M | $56.17M | $88.06M | $13.23M | $143.31M | $2.31M |
| Depreciation & amortization | $9.50M | $9.50M | $2.82M | $3.72M | $9.01M | $9.35M | $2.57M | $3.27M |
| Stock-based compensation | $11.83M | $11.73M | $11.27M | $11.82M | $11.90M | $14.94M | $22.91M | $30.98M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.